MARKET

CAPR

CAPR

Capricor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.960
-0.050
-1.25%
Opening 11:41 04/19 EDT
OPEN
4.030
PREV CLOSE
4.010
HIGH
4.050
LOW
3.862
VOLUME
99.67K
TURNOVER
--
52 WEEK HIGH
12.32
52 WEEK LOW
1.600
MARKET CAP
90.28M
P/E (TTM)
-4.2329
1D
5D
1M
3M
1Y
5Y
Clinical Trials Market Worth $ 69.7 Billion By 2028
Market Stats News · 4d ago
Bone Marrow Transplant Rejection Treatment Market Research 2027 Distribution Status by Players, Market Size Analysis and Forecast by Type and Application
The Express Wire · 4d ago
Bone Marrow Transplant Rejection Treatment Market Professional Survey, Growth, Shares, Opportunities and Forecast to 2027
Market Stats News · 04/08 18:32
Myocardial Infarction Drug Market Size, Industry Share 2021 ,Market Research with Growth, Manufacturers, Segments and 2027 Forecasts Research
Apr 07, 2021 (Market Insight Reports) -- The latest report as Myocardial Infarction Drug Market acknowledges Size, Application Segment, Type, Regional...
Market Insight Reports · 04/07 17:53
Global Bone Marrow Transplant Rejection Treatment Market Insights, Overview, Analysis and Forecast 2015-2026
Mar 30, 2021 (Heraldkeepers) -- This report researches the worldwide Bone Marrow Transplant Rejection Treatment market size (value) in key regions like...
Heraldkeepers · 03/30 13:14
Myocardial Infarction Drug Market Supply, Sales, Revenue and Forecast from 2020 to 2027 By Ameco Research
pune, India, Thu, 25 Mar 2021 02:20:47 / Comserve Inc. / -- The global Myocardial Infarction Drug market is segmented by company, region (country), by Type,...
Comserve · 03/25 06:23
Global Dilated Cardiomyopathy Market 2020 Growth Parameters, Competitive Landscape Outlook and COVID-19 Impact Prediction 2025
Mar 22, 2021 (CDN Newswire via Comtex) -- Global Dilated Cardiomyopathy Market Growth (Status and Outlook) 2020-2025 delivers an in-depth analysis of the...
CDN Newswire · 03/22 23:46
BRIEF-Capricor Therapeutics Files For Mixed Shelf Offering Of Up To $150 Mln
reuters.com · 03/16 21:59
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CAPR. Analyze the recent business situations of Capricor through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CAPR stock price target is 12.00 with a high estimate of 12.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 42
Institutional Holdings: 1.52M
% Owned: 6.68%
Shares Outstanding: 22.80M
TypeInstitutionsShares
Increased
10
243.38K
New
5
160.41K
Decreased
5
122.76K
Sold Out
5
35.13K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.92%
Pharmaceuticals & Medical Research
-0.46%
Key Executives
Chairman/Director
Frank Litvack
President/Chief Executive Officer/Director
Linda Marban
Chief Financial Officer/Chief Accounting Officer
Anthony Bergmann
Executive Vice President/General Counsel
Karen Krasney
Vice President
Thomas Copmann
Vice President
Houman Hemmati
Vice President
Luis Rodriguez-Borlado
Vice President - Research & Development
Rachel Smith
Other
Deborah Ascheim
Director
Joshua Kazam
Independent Director
Earl Collier
Independent Director
George Dunbar
Independent Director
Louis Grasmick
Independent Director
Louis Manzo
Independent Director
David Musket
No Data
About CAPR
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.

Webull offers kinds of Capricor Therapeutics Inc stock information, including NASDAQ:CAPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CAPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CAPR stock methods without spending real money on the virtual paper trading platform.